LDRT and Chemoimmunotherapy in NPC With Liver Metastasis (Light)

Low-dose Radiotherapy and Chemoimmunotherapy in Nasopharyngeal Carcinoma With Liver Metastasis

This study aims to evaluate the efficacy and toxicity of adding low-dose radiotherapy to chemoimmunotherapy as a first-line treatment for nasopharyngeal carcinoma patients with liver metastasis.

Study Overview

• Status: Recruiting
• Conditions: Nasopharyngeal Cancinoma (NPC)
• Intervention / Treatment: Other: Low-dose radiotherapy combine with chemoimmunotherapy

Detailed Description

Low-dose radiotherapy to the liver metastasis. Chemotherapy: gemcitabine and cisplatin Immunotherapy: penpulimab

• Study Type: Interventional
• Enrollment (Estimated): 26
• Phase: Phase 2

Contacts and Locations

• Study Contact: Name: Huai Liu, M.D.; Phone Number: +8673189762230; Email: liuhuai@hnca.org.cn

Study Locations

• China
  • Hunan
    • Changsha, Hunan, China, 410013
      • Recruiting
      • Hunan Cancer Hospital
      • Contact: Hui Wang, M.D.; Phone Number: +8673189762230; Email: wanghui@hnca.org.cn
    • Changsha, Hunan, China, 410000
      • Recruiting
      • Xiangya Hospital of Central South University
      • Contact: Qin Zhou; Email: zhouqin5796@csu.edu.cn
      • Principal Investigator: Qin Zhou
    • Changsha, Hunan, China, 410000
      • Recruiting
      • Third Xiangya Hospital, Central South University,
      • Contact: Qingnan Tang; Phone Number: 8615692028619; Email: qingnantang@qq.com
      • Principal Investigator: Xi Pan
    • Chenzhou, Hunan, China, 424300
      • Recruiting
      • The First People's Hospital of Chenzhou
      • Contact: Qiyuan Zhou; Phone Number: 8618175547107; Email: czyyflgcp@163.com
      • Principal Investigator: Jinyong Tang
    • Shaoyang, Hunan, China, 422000
      • Recruiting
      • The Central Hospital of Shaoyang
      • Principal Investigator: Xinfu Liu
      • Contact: Xinfu Liu; Phone Number: 8615807397520; Email: xinfuliudoc@163.com
    • Yueyang, Hunan, China, 414020
      • Recruiting
      • Yueyang Central Hospital
      • Contact: Jie Weng; Phone Number: 8613975070672; Email: 3173720582@qq.com
      • Principal Investigator: Jie Weng

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Age ≥ 18 years and ≤ 70 years, male or non-pregnant female.
2. Histologically confirmed with nonkeratinizing carcinoma of the nasopharynx (differentiated or undifferentiated type, WHO II or III)
3. Stage IVB (AJCC 8th edition staging)
4. De novo nasopharyngeal carcinoma with liver metastasis, or patients who had received curative treatment (radical radiotherapy or radical radiotherapy combined with chemotherapy) and developed liver metastasis more than 6 months after treatment completion.
5. ECOG performance status: 0 or 1
6. Must have at least one measurable lesion (assessed according to RECIST v1.1)
7. Absolute neutrophil count (ANC) ≥ 1.5 × 10^9/L; platelets ≥ 100 × 10^9/L; hemoglobin ≥ 90 g/L.
8. International normalized ratio (INR) or prothrombin time (PT) ≤ 1.5 × upper limit of normal (ULN); activated partial thromboplastin time (aPTT) ≤ 1.5 × ULN
9. Serum creatinine ≤ 1.5 × ULN or estimated glomerular filtration rate (eGFR) ≥ 60 mL/min.
10. Serum total bilirubin ≤ 1.5 × ULN (patients with Gilbert's syndrome may be included if total bilirubin < 3 × ULN); AST and ALT ≤ 5 × ULN （because of liver metastasis）

Exclusion Criteria:

1. Patients with tumor recurrence at the primary site who have previously received radical radiotherapy.
2. Tumor invasion involving major blood vessels, with a high risk of significant bleeding as assessed by the investigator.
3. Systemic anticancer therapy, including hormone therapy, administered within 28 days prior to the initiation of the study treatment.
4. Previous treatment with immune checkpoint inhibitors (e.g., PD-1/PD-L1, CTLA-4).
5. Patients with active autoimmune diseases or a history of autoimmune diseases with a risk of recurrence.
6. Known history of other malignancies (except cured basal cell carcinoma or carcinoma in situ of the cervix).
7. Conditions requiring systemic corticosteroid therapy (equivalent to >10 mg/day of prednisone or similar medications) or other immunosuppressive therapy within ≤14 days prior to treatment.
8. Uncontrolled diabetes or laboratory abnormalities ≥Grade 1 in potassium, sodium, or corrected calcium levels despite standard treatment, or ≥Grade 3 hypoalbuminemia within ≤14 days before treatment.
9. History of the following diseases: interstitial lung disease, non-infectious pneumonitis, or uncontrolled diseases, including pulmonary fibrosis or acute lung disease.
10. Severe chronic or active infections requiring systemic antibiotics, antifungals, or antivirals within ≤14 days before the first dose of the investigational drug (including tuberculosis infection).
11. Known history of HIV infection.
12. Untreated chronic hepatitis B patients or hepatitis B virus (HBV) carriers with HBV DNA ≥500 IU/mL, or active hepatitis C virus (HCV) carriers.
13. Any major surgery requiring general anesthesia within ≤28 days prior to treatment.
14. Previous allogeneic stem cell transplantation or organ transplantation.
15. Any cardiovascular risk factors, including: cardiac chest pain that restricts daily instrumental activities ≤28 days before treatment. Symptomatic pulmonary embolism within ≤3 months before treatment. Acute myocardial infarction within ≤6 months before treatment. History of heart failure meeting New York Heart Association (NYHA) Class III or IV within ≤6 months before treatment. Grade ≥2 ventricular arrhythmias within ≤6 months before treatment. History of cerebrovascular accident within ≤6 months before the first dose of the investigational drug.
16. Evident bleeding tendencies or clinically significant bleeding symptoms ≤28 days prior to randomization, including but not limited to gastrointestinal bleeding, nasal bleeding (excluding epistaxis or retrograde blood-stained nasal discharge), and persistent bleeding disorders or coagulopathy.
17. Known allergy to any component of the investigational drug or a history of severe hypersensitivity to other monoclonal antibodies.
18. Peripheral neuropathy of Grade ≥2 as defined by NCI CTCAE v5.0.
19. Administration of live vaccines within ≤4 weeks prior to treatment.
20. Underlying medical conditions (including laboratory abnormalities) or alcohol/drug abuse or dependency that could impair drug administration, interpretation of drug toxicity, or adverse events (AEs), or could compromise study compliance or execution.
21. Pregnant or breastfeeding women.
22. Other factors deemed by the investigator that could lead to the premature termination of the study, such as other severe illnesses, significant laboratory abnormalities, or family/social factors that could affect participant safety or the collection of study data.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: LDRT and chemoimmunotherapy; Low-dose radiotherapy, chemotherapy, immunotherapy	Other: Low-dose radiotherapy combine with chemoimmunotherapy; Radiation: 1.4Gy for 5 days to the liver metastasis before chemoimmunotherapy. Chemoimmunotherapy: gemcitabine(1000mg per square meter on days 1,8) , cisplatin (80mg per square meter on day 1), penpulimab (200mg, day1)

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Intrahepatic progression-free survival (iPFS)	Defined as the time from the start of therapy to the first progression in liver	1 year

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Progression-free survival (PFS)	Defined as the time from the start of therapy to documented local or regional relapse, distant metastasis, or death from any cause, whichever occurred first.	1 year
Overall survival (OS)	Defined as the time from the start of therapy to death from any cause or censored at the date of last follow-up.	2 year
Objective response rate (ORR)	Defined as the proportion of patients achieving complete response (CR) or partial response (PR) in all patients. According to RECIST 1.1 evaluation criteria, physicians use the efficacy evaluation record as the determination criteria	18 weeks
Incidence rate of adverse events (AEs)	Analysis of acute and late adverse events (AEs) are evaluated by CTCAE v5.0.	2 year

Collaborators and Investigators

• Sponsor: Hunan Cancer Hospital

Study record dates

Study Major Dates

• Study Start (Actual): January 14, 2025
• Primary Completion (Estimated): June 30, 2026
• Study Completion (Estimated): June 30, 2027

Study Registration Dates

• First Submitted: January 9, 2025
• First Submitted That Met QC Criteria: January 16, 2025
• First Posted (Actual): January 22, 2025

Study Record Updates

• Last Update Posted (Actual): April 2, 2026
• Last Update Submitted That Met QC Criteria: March 28, 2026
• Last Verified: March 1, 2026

More Information

Terms related to this study

• Keywords: chemotherapy; immunotherapy; liver metastasis; nasopharyngeal carcinoma; low-dose radiotherapy
• Additional Relevant MeSH Terms: Stomatognathic Diseases; Neoplasms by Site; Neoplasms; Neoplasms by Histologic Type; Head and Neck Neoplasms; Neoplasms, Glandular and Epithelial; Carcinoma; Otorhinolaryngologic Diseases; Pharyngeal Neoplasms; Otorhinolaryngologic Neoplasms; Nasopharyngeal Diseases; Pharyngeal Diseases; Nasopharyngeal Neoplasms; Nasopharyngeal Carcinoma
• Other Study ID Numbers: KY2024528; Z2023080 (Other Grant/Funding Number: Hunan Provincial Health Commission)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: Because of the policy of hospital

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No